7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Talaris Therapeutics Inc
(NASDAQ:TALS) 

TALS stock logo

Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant bloo...

Founded: 1998
CEO: Scott Requadt  
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology

Share this website to your friends
Talaris Therapeutics Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -12.28-10.53-8.77-7.02-5.26-3.51-1.750
Talaris Therapeutics Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -12.47-10.69-8.91-7.13-5.34-3.56-1.780
Talaris Therapeutics Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 04.929.8314.7519.6724.5829.534.42
Talaris Therapeutics (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.19-1.88-1.57-1.25-0.94-0.63-0.310
Talaris Therapeutics P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.120.240.360.480.590.710.83
No extra charts and metrics for this ticker.